Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.

A non-NIH clinical trial is now testing ivermectin, the antiparasitic drug that became a lightning rod during the COVID-19 pandemic, as a potential weapon against one of the most aggressive forms of ...

Since the pandemic began, Florida lawmakers and health officials have become fascinated with ivermectin for more than its approved human uses. Now, Florida’s Republican legislators want to make it ...

In early 2020, as the U.S. recorded its first confirmed COVID-19 cases and the scale of the unfolding pandemic came into focus, scientists and clinicians around the world raced to understand the ...

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...

Iowa Republicans are considering a bill to allow over-the-counter access to the anti-parasitic drug ivermectin. Medical professionals and the FDA have warned against general human use of ivermectin, ...